相关实验视频

Updated: May 10, 2026

Multi-target Parallel Processing Approach for Gene-to-structure Determination of the Influenza Polymerase PB2 Subunit

Multi-target Parallel Processing Approach for Gene-to-structure Determination of the Influenza Polymerase PB2 Subunit

Published on: June 28, 2013

针对Streptococcus pyogenes atpF蛋白进行多层次疫苗开发:基因组驱动的免疫信息技术策略

Manisha Agarwal¹, Sanjeeb Handique¹, Sanchaita Rajkhowa¹

¹Centre for Biotechnology and Bioinformatics, Dibrugarh University, Dibrugarh 786004 Assam, India.

Journal, genetic engineering & biotechnology

|August 25, 2025

概括

这项研究使用计算方法开发了一种针对Streptococcus pyogenes的新型多表位疫苗. 这种SM1候选疫苗有望引起强烈的免疫反应来对抗这种优先病原体.

科学领域:

微生物学和免疫学
疫苗开发
计算生物学

背景情况:

链球菌是高优先级的病原体,抗生素耐药性正在增加,目前还没有疫苗.
遗传多样性和自身免疫问题使S. pyogenes的传统疫苗设计复杂化.

研究的目的:

设计和计算评估一种针对Streptococcus pyogenes的新型多层疫苗.
确定一个保存的,必需的蛋白质作为疫苗的目标.

主要方法:

使用反向疫苗学和减法蛋白学来识别atpF蛋白.
设计了三种疫苗结构 (SM1,SM2,SM3) 整合了表位素,辅助剂和链接剂.
对候选疫苗的疗效进行了分子建模和体免疫模拟.

主要成果:

鉴定出atpF蛋白是一种保存的抗原标.
SM1表现出优异的结合亲和力,免疫受体相互作用,以及强烈的幽默和细胞免疫力.
代优化证实了在大肠杆菌中SM1的有效表达.

结论:

对于S. pyogenes来说,atpF蛋白是一种有前途的疫苗点.
作为一个可行的候选人,SM1疫苗构造具有显著的潜力.
计算机建模加速了疫苗开发,为传统方法提供了替代方案.

关键词:

ATP合成酶F1子单元多种表位疫苗反向疫苗学杆菌 pyogenes

更多相关视频

A High Throughput MHC II Binding Assay for Quantitative Analysis of Peptide Epitopes

A High Throughput MHC II Binding Assay for Quantitative Analysis of Peptide Epitopes

Published on: March 25, 2014

Overlapping Peptide Library to Map Qa-1 Epitopes in a Protein

Overlapping Peptide Library to Map Qa-1 Epitopes in a Protein

Published on: December 20, 2017

相关概念视频

Pharmacogenomics: Identification of New Drug Targets

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...